Biologics in dermatology: adverse effects

被引:12
|
作者
Sehgal, Virendra N. [1 ]
Pandhi, Deepika [2 ,3 ]
Khurana, Ananta [4 ,5 ]
机构
[1] Sehgal Nursing Home, Dermatovenerol Skin VD Ctr, Delhi 110033, India
[2] Univ Coll Med Sci, Dept Dermatol & STD, Delhi 110095, India
[3] Assoc Guru Teg Bahadur Hosp, Delhi, India
[4] Dr RML Hosp, Dept Dermatol & STD, New Delhi, India
[5] PGIMER, New Delhi, India
关键词
TUMOR-NECROSIS-FACTOR; TNF-ALPHA THERAPY; TO-SEVERE PSORIASIS; CHRONIC HEPATITIS-B; RANDOMIZED CONTROLLED-TRIAL; INFLAMMATORY-BOWEL-DISEASE; SQUAMOUS-CELL CARCINOMA; LATE-ONSET NEUTROPENIA; DRUG-INDUCED LUPUS; OF-THE-LITERATURE;
D O I
10.1111/ijd.12802
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Biologics are a group of drugs that precisely affect certain specific steps in the immune response and are an extremely useful group when used in an appropriate setting. However, their use can often be a double-edged sword. Careful patient selection and thorough knowledge of adverse effects is a key to their successful use in various disorders. The initial enthusiasm has gradually given way to a more cautious approach wherein a balance is sought between clinical usefulness and expected side effects. The adverse effects of the biologics most commonly used in dermatology have been carefully listed for ready reference. The plausible causes of the adverse reactions are succinctly outlined along with their incriminating factor(s). Besides, in brief, the attention has been focused on their management. The content should provide an essential didactic content for educating the practitioner.
引用
收藏
页码:1442 / 1460
页数:19
相关论文
共 50 条
  • [21] Ten Years On The Impact of Biologics on the Practice of Dermatology
    Leonardi, Craig L.
    Romiti, Ricardo
    Tebbey, Paul W.
    DERMATOLOGIC CLINICS, 2015, 33 (01) : 111 - +
  • [22] Long-term efficacy of biologics in dermatology
    Castelo-Soccio, Leslie
    Van Voorhees, Abby S.
    DERMATOLOGIC THERAPY, 2009, 22 (01) : 22 - 33
  • [23] Ethical considerations when prescribing biologics in dermatology
    Santoro, Frank A.
    Rothe, Marti J.
    Strober, Bruce E.
    CLINICS IN DERMATOLOGY, 2012, 30 (05) : 492 - 495
  • [24] Long-term safety of biologics in dermatology
    Lima, Xinaida T.
    Seidler, Elizabeth M.
    Lima, Hermenio C.
    Kimball, Alexandra B.
    DERMATOLOGIC THERAPY, 2009, 22 (01) : 2 - 21
  • [25] Biologics in dermatology: Off-label indications
    Mitra, Debdeep
    Chopra, Ajay
    Saraswat, Neerja
    Mitra, Barnali
    Talukdar, Krishna
    Agarwal, Reetu
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2020, 11 (03) : 319 - 327
  • [26] A Practical Guide to Using Biologics in Pediatric Dermatology
    George, Annie
    Lansang, Rafael Paolo
    Lansang, Perla
    Gooderham, Melinda
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024, 28 (01) : 59 - 67
  • [27] Biologics in dermatology: What does the future hold?
    Yavuz, Cahit
    DERMATOLOGIC THERAPY, 2019, 32 (04)
  • [28] Adverse drug reactions to biologics
    Scherer, Kathrin
    Spoerl, David
    Bircher, Andreas J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (06): : 411 - 426
  • [29] Adverse effects of biologics: a network meta-analysis and Cochrane overview
    Singh, J. A.
    Wells, G. A.
    Christensen, R.
    Ghogomu, Tanjong E.
    Maxwell, L.
    MacDonald, J. K.
    Filippini, G.
    Skoetz, N.
    Francis, D.
    Lopes, L. C.
    Guyatt, G. H.
    Schmitt, J.
    La Mantia, L.
    Weberschock, T.
    Roos, J. F.
    Siebert, H.
    Hershan, S.
    Lunn, M. P. T.
    Tugwell, P.
    Buchbinder, R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02):
  • [30] ADVERSE EFFECTS OF BIOLOGICS: A NETWORK META-ANALYSIS AND COCHRANE OVERVIEW
    Singh, J. A.
    Wells, G. A.
    Christensen, R.
    Tanjong, E.
    MacDonald, J.
    Tugwell, P.
    Buchbinder, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 628 - 628